Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine effects on glutamate metabolism in moderate to severe depression
ChiCTR2000035209Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xinxiang Medical University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of memantine in major depressive disorder (MDD) (2 arms), sponsored by The Second Affiliated Hospital of Xinxiang Medical University. Primary endpoint: glutamate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
memantine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2000035209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035209.